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The Financial and Psychosocial Impact of Medicinal Cannabis
Chris Ahmed, Andrew Lee**, Amanda Campbell, Greg Garber, MSW, LCSW, Neil
Palmisiano, MD, Brooke Worster, MD*

Introduction: Therapeutic utilization of medicinal cannabis for symptom management
in oncology patients is a burgeoning area of research focus. We hypothesize that
medicinal cannabis use can result in subjective improvements in quality of life (QOL)
metrics for cancer patients.
Methods: Adult palliative care patients at a medical oncology clinic are consented to
the study after being certified to access medicinal cannabis. After three months,
subjective changes in QOL, including well-being, financial burden, pain, chemotherapy
induced nausea and vomiting (CINV), and other categories are recorded via telephone
interview. Responses are documented with a numerical Likert scale (from 1-5, with a
score of 1 = greatly decreased satisfaction, and 5 = greatly increased satisfaction; a
score of 3 is no change from baseline). Scores >3.5 were deemed meaningful in terms
of improvement.
Results: An aggregate of 35 patient scores showed meaningful increases in subjective
satisfaction across most metrics. Satisfaction with CINV symptoms showed the most
marked improvement, with an average score of 3.63. While pain scores were similar at
3.53, more general QOL metrics were lower, at 3.46. Most patients did not find the cost
to be burdensome, with an average score of 3.03.

Discussion: The initial 35 interviews of our desired n of 120 suggest that medicinal
cannabis may provide analgesic, antiemetic, and anxiolytic benefits for cancer patients.
We anticipate that additional interviews will follow this pattern. If so, our study could
bolster the evidence that therapeutic use of medicinal cannabis may be helpful for
patients undergoing cancer treatment.

